Description
Developer of cancer therapeutics. The company's pharmaceutical products aim to treat and reduce symptoms of various kinds of cancers, enabling healthcare professionals to prescribe more effective treatments to their patients.
Contact Information
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. Later Stage VC | 12-Jan-2022 | 000.00 | Completed | Generating Revenue | ||
4. Later Stage VC | 20-Aug-2021 | 000.00 | 000.00 | Completed | Clinical Trials - General | |
3. Early Stage VC (Series A1) | 14-Jan-2020 | Completed | Clinical Trials - General | |||
2. Early Stage VC | 30-Jul-2019 | Completed | Clinical Trials - General | |||
1. Early Stage VC (Series A) | 03-Jan-2018 | Completed | Clinical Trials - General |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Wenjun Zhang Ph.D | Founder, Chief Executive Officer & Chairman |
Name | Representing | Role | Since |
---|---|---|---|
Wenjun Zhang Ph.D | ExcelMab | Founder, Chief Executive Officer & Chairman | 000 0000 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Delta Capital | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
GDD Industry Fund | Government | Minority | 000 0000 | 000000 0 | |
Huangpu Biomedical Industry Investment Fund | Venture Capital | Minority | 000 0000 | 000000 0 | |
Shanghai Passion Capital | PE/Buyout | Minority | 000 0000 | 000000 0 | |
Caijin Capital | Venture Capital | Minority | 000 0000 | 000000 0 |